NO973608D0 - Nye farnesyl-transferaseinhibitorer, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene - Google Patents

Nye farnesyl-transferaseinhibitorer, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene

Info

Publication number
NO973608D0
NO973608D0 NO973608A NO973608A NO973608D0 NO 973608 D0 NO973608 D0 NO 973608D0 NO 973608 A NO973608 A NO 973608A NO 973608 A NO973608 A NO 973608A NO 973608 D0 NO973608 D0 NO 973608D0
Authority
NO
Norway
Prior art keywords
compounds
preparation
pharmaceutical preparations
preparations containing
transferase inhibitors
Prior art date
Application number
NO973608A
Other languages
English (en)
Other versions
NO973608L (no
Inventor
Francios Clerc
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO973608L publication Critical patent/NO973608L/no
Publication of NO973608D0 publication Critical patent/NO973608D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO973608A 1995-02-09 1997-08-05 Nye farnesyl-transferaseinhibitorer, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene NO973608D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9501489A FR2730491B1 (fr) 1995-02-09 1995-02-09 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR1996/000198 WO1996024611A1 (fr) 1995-02-09 1996-02-07 Inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
NO973608L NO973608L (no) 1997-08-05
NO973608D0 true NO973608D0 (no) 1997-08-05

Family

ID=9475979

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973608A NO973608D0 (no) 1995-02-09 1997-08-05 Nye farnesyl-transferaseinhibitorer, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene

Country Status (17)

Country Link
US (1) US5856439A (no)
EP (1) EP0808328A1 (no)
JP (1) JPH10513467A (no)
KR (1) KR19980702048A (no)
CN (1) CN1173874A (no)
AU (1) AU4722796A (no)
BR (1) BR9607317A (no)
CA (1) CA2210955A1 (no)
CZ (1) CZ249897A3 (no)
FI (1) FI973278A0 (no)
FR (1) FR2730491B1 (no)
NO (1) NO973608D0 (no)
PL (1) PL321675A1 (no)
SK (1) SK108797A3 (no)
TR (1) TR199700727T1 (no)
WO (1) WO1996024611A1 (no)
ZA (1) ZA961072B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730491B1 (fr) * 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
GEP20115337B (en) 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
US8822497B2 (en) 2007-03-01 2014-09-02 Novartis Ag PIM kinase inhibitors and methods of their use
US8293769B2 (en) 2007-05-21 2012-10-23 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 縮合複素環式化合物およびそれらの使用
MX2012004377A (es) 2009-10-14 2012-06-01 Merck Sharp & Dohme Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US8987275B2 (en) 2010-03-16 2015-03-24 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6034784B2 (ja) 2010-07-28 2016-11-30 ジャンセン ダイアグノスティックス,エルエルシー ファルネシルトランスフェラーゼ阻害剤による治療に対する急性白血病応答を判定するための方法
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2011292261B2 (en) 2010-08-17 2015-05-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140045832A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Insulin-Like Growth Factor-1 Receptor Inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
MX2015004041A (es) 2012-09-28 2015-07-06 Merck Sharp & Dohme Compuestos novedosos que son inhibidores de erk.
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
RU2660349C2 (ru) 2012-11-28 2018-07-05 Мерк Шарп И Доум Корп. Композиции и способы для лечения злокачественной опухоли
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド サイクリン依存性キナーゼ7(cdk7)の多環阻害剤
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
HUE044698T2 (hu) 2015-08-17 2019-11-28 Kura Oncology Inc Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
CN110325212B (zh) 2016-11-03 2022-03-22 库拉肿瘤学公司 用于治疗癌症的方法的法尼基转移酶抑制剂
CN110650976B (zh) 2017-04-13 2024-04-19 赛罗帕私人有限公司 抗SIRPα抗体
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
CA2044333A1 (en) * 1990-06-12 1991-12-13 Jackson B. Gibbs Chemotherapeutic agents
CA2072033A1 (en) * 1991-06-28 1992-12-29 Jackson B. Gibbs Non-substrate inhibitors of farnesyl protein transferase
CA2118985A1 (en) * 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
CA2160786A1 (en) * 1993-05-14 1994-11-24 James C. Marsters, Jr. Ras farnesyl transferase inhibitors
US5439918A (en) * 1994-03-14 1995-08-08 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
FR2730491B1 (fr) * 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730492B1 (fr) * 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
FR2730491A1 (fr) 1996-08-14
US5856439A (en) 1999-01-05
FI973278A (fi) 1997-08-08
FI973278A0 (fi) 1997-08-08
AU4722796A (en) 1996-08-27
TR199700727T1 (xx) 1998-02-21
CA2210955A1 (fr) 1996-08-15
ZA961072B (en) 1996-08-20
BR9607317A (pt) 1997-12-30
JPH10513467A (ja) 1998-12-22
CN1173874A (zh) 1998-02-18
KR19980702048A (ko) 1998-07-15
MX9706015A (es) 1997-11-29
PL321675A1 (en) 1997-12-22
EP0808328A1 (fr) 1997-11-26
NO973608L (no) 1997-08-05
WO1996024611A1 (fr) 1996-08-15
SK108797A3 (en) 1997-12-10
FR2730491B1 (fr) 1997-03-14
CZ249897A3 (en) 1997-11-12

Similar Documents

Publication Publication Date Title
NO973608D0 (no) Nye farnesyl-transferaseinhibitorer, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene
NO973222D0 (no) Nye farnesyl-transferase-inhibitorer, deres fremstilling samt farmasöytiske preparater inneholdende inhibitorene
NO973607D0 (no) Nye farnesyltransferaseinhibitorer, deres fremstilling og preparater inneholdende inhibitorene
NO980094L (no) Nye farnesyl-transferase-inhibitorer, deres fremstilling og farmasöytiske preparater inneholdende disse
NO982580D0 (no) Nye taxoider, deres fremstilling samt farmas°ystiske preparater inneholdende taxoidene
NO944700D0 (no) Nye tienotiazinderivater, fremgangsmåte for fremstilling derav samt farmasöytiske preparater inneholdende forbindelsene
NO973923L (no) Nye taxoider, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene
NO307459B1 (no) Piperazinderivater, samt farmasøytiske preparater inneholdende slike
FI952010A0 (fi) Farnesyyliproteiinitransferaasin estäjät
AU6523396A (en) Novel farnesyl transferase inhibitors, preparation thereof and pharmaceutical compositions containing said inhibitors
NO965377D0 (no) Indolinonforbindelser samt farmasöytiske preparater inneholdende forbindelsene
EE9800146A (et) Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid
NO923283L (no) 1,4-benzodioksanderivater, fremgangsmaate for fremstillingderav, samt farmasoeytiske preparater som inneholder minstett slikt derivat
NO952677D0 (no) Nye dihydropyrrolopyridinon- og oksazolopyridinonforbindelser, deres fremstilling og farmasöytiske preparater
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
NO942910L (no) Nye baccatin-III- og 10-desacetyl-baccatin-III-derivater, deres fremstillinger, samt farmasöytiske preparater inneholdende derivatene
NO20003661L (no) Nye pentasakkarider, fremgangsmÕter for deres fremstilling og farmasøytiske preparater inneholdende de samme
NO974563D0 (no) Nye taxoider, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene
DK303688A (da) Polyoxygenerede labdanderivater, fremgangsmaade til deres fremstilling samt deres anvendelse som laegemidler
NO900297L (no) Vaeskeformig farmasoeytisk preparat inneholdende piperidinoalkanolderivater.
NO20024590D0 (no) Farmasöytiske preparater inneholdende oligosakkarider, de nye oligosakkarider samt deres fremstilling
DK393788A (da) Substituerede thienoimidazolderivater, fremgangsmaader til deres fremstilling samt deres anvendelse som laegemidler
NO305750B1 (no) Substituerte benzensulfonylureaer og deres anvendelse for fremstilling av farmas°ytiske preparater samt farmas°ytiske preparater inneholdende forbindelsene
AU6847498A (en) Anti-inflammatory medicament containing farnesyl protein transferase inhibitor, its preparation and use
DK259088D0 (da) Diarylalkyl-substituerede alkylaminer, fremgangsmaader til deres fremstilling samt deres anvendelse som laegemidler